Author: mattstrongalldaylong

The Rutledge Cancer Foundation has awarded a landmark $1.5 million ACES (Accelerating Cures for Ewing Sarcoma) grant to support pioneering

Fannin Partners has secured two major grants from the Congressionally Directed Medical Research Programs (CDMRP) and the Faris Foundation to

This article details a first-in-human case report evaluating a novel therapeutic cancer vaccine. Ewing sarcoma is driven by specific genetic

This systematic review, titled “GD2-targeted immunotherapy in pediatric bone sarcomas: a systematic review of emerging strategies and combination approaches” (published

Researchers at the University of Pittsburgh and UPMC Hillman Cancer Center have developed a promising double-barreled treatment strategy to tackle

The article provides a comprehensive review of advances in treating rare primary bone cancers, such as osteosarcoma, Ewing sarcoma, and

This article reports on a breakthrough experimental treatment for a 17-year-old patient whose kidney cancer had relapsed and spread across

Current therapies for Ewing Sarcoma rely on heavy, full-body chemotherapy, which causes severe side effects because it attacks healthy cells

This study reveals that Ewing sarcoma cells have a major defect in a specific DNA repair mechanism called Microhomology-Mediated End